Oncology (ONC) Community

Community Goals

Provide forums for interactions of Community members to foster new relationships and provide interactive scientific discussion on current key issues in oncology.
Develop of best practices for Annual Meeting scientific programming proposals that leads to scientifically rich, well-developed collaborative proposals issues in oncology.
Utilize social media to post impactful publications or presentations, permit commentary, and promote discussion among members.
Standardize criteria to prioritize scientific proposals in collaboration with members of other Communities housed within the Translational & Precision Network.

ASCPT Members-Only Webinar Presented by the Oncology (ONC) and Pharmacometrics & Pharmacokinetics (PMK) Communities
Title: A Semi-Mechanistic PK/PD Model to Project Undetectable Minimal Residual Disease Rates in Chronic Lymphocytic Leukemia Studies
Date and Time: Tuesday, May 11, 2021, 12:00 pm EST
Speakers: Sathej Gopalakrishnan, PhD, and Ahmed H. Salem, PhD
Moderators: Deanna Brackman, PhD, and Neeraj Gupta, PhD
Description: Understanding the kinetics of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) is an important aspect during the development of fixed duration targeted therapies. This webinar will introduce the clinical implications of MRD for the treatment of CLL and will include broader discussions on both MRD as an endpoint in hematological malignancies as well as the PK/PD modeling concepts utilized.

Additionally, the presenters will speak about the objective to develop, qualify, and utilize a semi-mechanistic PK/PD model to evaluate the impact of venetoclax-rituximab combination therapy on the kinetics of MRD in CLL patients. Such fit-for-purpose models have great potential in assisting clinical development of targeted therapies in hematologic oncology. Attend the session to learn more about the development of the model and how the findings and concepts provide the framework for applying similar models to drug development in all hematological malignancies and would provide substantial impact, especially on the topic of predicting sustained response that may allow for fixed duration therapies.
Register Now!

Past Webinars

Joint Infectious Diseases and Oncology Community Webinar: Convergence of Therapeutic Approaches in Oncology and HIV to Target Immune Evasion: Integrating Clinical Pharmacology Lessons Learned
Joint Early Career and Oncology Community Webinar: Translational and Clinical Pharmacology Considerations in the Development of Immune-Oncology Drugs (Encore Presentation)
Using Preclinical Data in Phase I Oncology Trials: A Bayesian Decision-Theoretic Approach
Joint Early Career and Oncology Community Webinar: Translational and Clinical Pharmacology Considerations in the Development of Immune-Oncology Drugs
IQ CPLG PWG: Strategies to Address Opportunities in Oncology Pediatric Drug
Clinical Pharmacological and Pharmacodynamic Perspectives on the Adverse Events of Cancer Immunotherapy
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Cancer Patients

Community Working Groups

Communications Working Group
Goals: Identify the communications tools, shared content and frequency desired by Community members.
Identify a means for Community members to identify content (publications, presentation links, etc.) for consideration.
Shruti Agrawal, PhD, Working Group Lead
Antoinette Ajavon, PhD, Working Group Member

Forum Working Group
Goals: Identify the forum (webinar, local face-to-face meetings, etc) structure desired by Community members.
Identify the frequency and timeframe for the forum desired by Community members.
Angela James, PhD, Working Group Lead
Yan Ji, PhD, Working Group Member
Imke Bartelink, PharmD, PhD, Working Group Member
If you are interested in volunteering with the ONC working group, please email Stacy.